Summit Therapeutics报告了 Ivonescimab在肺癌治疗中的混合试验结果Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment

动脉网05-30

by Mark Chiang马克·蒋Share To分享到Summit Therapeutics announced mixed results from a recent trial of its antibody treatment for lung cancer, Ivonescimab. The drug, which had previously outperformed Merck’s...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2539220915?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-30 21:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2539220915","market":"us","top_or_hot":-1,"title":"Summit Therapeutics报告了 Ivonescimab在肺癌治疗中的混合试验结果Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment","media":"动脉网","content":"<div>\n<p>by Mark Chiang马克·蒋Share To分享到Summit Therapeutics announced mixed results from a recent trial of its antibody treatment for lung cancer, Ivonescimab. The drug, which had previously outperformed Merck’s...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530211531976b3081&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit Therapeutics报告了 Ivonescimab在肺癌治疗中的混合试验结果Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit Therapeutics报告了 Ivonescimab在肺癌治疗中的混合试验结果Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-30 21:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530211531976b3081&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by Mark Chiang马克·蒋Share To分享到Summit Therapeutics announced mixed results from a recent trial of its antibody treatment for lung cancer, Ivonescimab. The drug, which had previously outperformed Merck’s...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530211531976b3081&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530211531976b3081&s=b","article_id":"2539220915","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530211531976b3081&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2539220915","pubTimestamp":1748610600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"by Mark Chiang马克·蒋Share To分享到Summit Therapeutics announced mixed results from a recent trial of its antibody treatment for lung cancer, Ivonescimab. The drug, which had previously outperformed Merck’s Keytruda in a direct comparison study, was closely monitored in this latest evaluation. The findings revealed both promising and less favorable outcomes, raising questions about its overall efficacy..Summit Therapeutics 近期对其用于治疗肺癌的抗体药物Ivonescimab进行的试验宣布了好坏参半的结果。The trial aimed to further assess Ivonescimab’s effectiveness as a treatment option for lung cancer patients. While the drug demonstrated certain advantages over existing therapies in specific areas, other aspects of the study showed less encouraging results. Summit Therapeutics has not yet disclosed detailed data from the trial but confirmed that the results were varied.该试验旨在进一步评估Ivonescimab作为肺癌患者治疗方案的有效性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SMMT":"Summit Therapeutics PLC","BK4007":"制药","BK4539":"次新股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Summit Therapeutics reports results from mixed trial of Ivonescimab in lung cancer treatment Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"SMMT":0.9},"content_text":"by Mark Chiang马克·蒋Share To分享到Summit Therapeutics announced mixed results from a recent trial of its antibody treatment for lung cancer, Ivonescimab. The drug, which had previously outperformed Merck’s Keytruda in a direct comparison study, was closely monitored in this latest evaluation. The findings revealed both promising and less favorable outcomes, raising questions about its overall efficacy..Summit Therapeutics 近期对其用于治疗肺癌的抗体药物Ivonescimab进行的试验宣布了好坏参半的结果。该药物此前在与默克公司Keytruda的直接对比研究中表现更优，因此在这次最新评估中备受关注。研究结果显示出既有积极的效果，也有不尽如人意的部分，引发了对其整体疗效的疑问。The trial aimed to further assess Ivonescimab’s effectiveness as a treatment option for lung cancer patients. While the drug demonstrated certain advantages over existing therapies in specific areas, other aspects of the study showed less encouraging results. Summit Therapeutics has not yet disclosed detailed data from the trial but confirmed that the results were varied.该试验旨在进一步评估Ivonescimab作为肺癌患者治疗方案的有效性。尽管该药物在特定领域显示出比现有疗法具有一定优势，但研究的其他方面结果并不理想。Summit Therapeutics尚未披露试验的详细数据，但确认结果存在差异。This development follows earlier reports highlighting Ivonescimab’s potential to challenge established treatments like Keytruda in head-to-head comparisons..这一进展紧随早先的报道，这些报道强调了伊沃尼西单抗在与Keytruda等现有治疗方案的直接对比中展现的潜力。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1Date: May 30, 2025日期：2025年5月30日Related posts:相关文章：Trump Administration Blocks Biden-Era Proposal to Expand Medicare Coverage for Weight Loss Drugs特朗普政府阻止了拜登时代的扩大医疗保险对减肥药物覆盖的提案Generic Drug Manufacturers: Navigating a Competitive Market with Over 30-Month Average Approval Process通用药物制造商：在超过30个月平均审批过程的竞争市场中航行Vaccination Reduces Infections Most Significantly Two to Three Years After Initial Shot, Protection Lasts Up to Eight Years.接种疫苗在两到三年后预防感染的效果最显著，保护作用可持续长达八年。Recipharm and ProductLife Group Partner to Expedite Drug Approval and Reduce Clinical Trial Durations for (Bio)pharmaceutical CompaniesRecipharm与ProductLife集团合作，加快（生物）制药公司的药物审批并缩短临床试验周期。©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 版权所有。与我们合作：[email protected][email protected]Author作者Mark Chiang马克·蒋Related Post相关帖子News Flash新闻快讯GoodRx Launches Community Link Program with Free Webinars for Independent Pharmacies on June 3 and 4, 2025GoodRx 推出社区链接计划，于2025年6月3日和4日为独立药房提供免费网络研讨会2025-05-302025年5月30日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2539220915","isCrawlerRequest":true}